Celyad Oncology is a biotechnology company focused on the research and discovery of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Year founded2004
Served areaWorldwide
HeadquartersAxis Business Park Rue Edouard Belin 2, 1435 Mont-Saint-Guibert, Brabant wallon – Belgium
22,593,956
IPOJuly 5, 2013
Stock exchange(s)Euronext Brussels